These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38821549)

  • 1. How deep is too deep? Assessing myometrial invasion as a predictor of distant recurrence in stage I endometrioid endometrial cancer.
    Dinoi G; Garzon S; Weaver A; McGree M; Glaser G; Langstraat C; Kumar A; Weroha J; Garda AE; Shahi M; Palmieri E; Scambia G; Fanfani F; Mariani A
    Int J Gynecol Cancer; 2024 Sep; 34(9):1389-1398. PubMed ID: 38821549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes and relapse patterns of stage IB grade 2 or 3 endometrial cancer treated with adjuvant vaginal brachytherapy.
    Hochreiter A; Kelly JR; Young MR; Litkouhi B; Black JD; Stromberger C; Higgins S; Schwartz PE; Damast S
    Int J Gynecol Cancer; 2020 Jan; 30(1):48-55. PubMed ID: 31722964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ultrastaging of 'negative' pelvic lymph nodes in patients with low- and intermediate-risk endometrioid endometrial cancer who developed non-vaginal recurrences.
    Gill SE; Garzon S; Multinu F; Hokenstad AN; Casarin J; Cappuccio S; McGree ME; Weaver AL; Cliby WA; Keeney GL; Mariani A
    Int J Gynecol Cancer; 2021 Dec; 31(12):1541-1548. PubMed ID: 34706876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor size: a better independent predictor of distant failure and death than depth of myometrial invasion in International Federation of Gynecology and Obstetrics stage I endometrioid endometrial cancer.
    Chattopadhyay S; Cross P; Nayar A; Galaal K; Naik R
    Int J Gynecol Cancer; 2013 May; 23(4):690-7. PubMed ID: 23518862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An intensive follow-up does not change survival of patients with clinical stage I endometrial cancer.
    Gadducci A; Cosio S; Fanucchi A; Cristofani R; Genazzani AR
    Anticancer Res; 2000; 20(3B):1977-84. PubMed ID: 10928137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-dose adjuvant vaginal cylinder brachytherapy for early-stage non-endometrioid endometrial cancer: recurrence risk and survival outcomes.
    Smart A; Buscariollo D; Alban G; Buzurovic I; Cheng T; Pretz J; Krechmer B; King M; Lee L
    Int J Gynecol Cancer; 2020 Dec; 30(12):1908-1914. PubMed ID: 32655012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The significance of the amount of myometrial invasion in patients with Stage IB endometrial carcinoma.
    Alektiar KM; McKee A; Lin O; Venkatraman E; Zelefsky MJ; Mychalczak BR; McKee B; Hoskins WJ; Barakat RR
    Cancer; 2002 Jul; 95(2):316-21. PubMed ID: 12124832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant chemotherapy in early-stage endometrioid endometrial cancer with >50% myometrial invasion and negative lymph nodes.
    Multinu F; Garzon S; Weaver AL; McGree ME; Sartori E; Landoni F; Zola P; Dinoi G; Aletti G; Block MS; Gadducci A; Mariani A
    Int J Gynecol Cancer; 2021 Apr; 31(4):537-544. PubMed ID: 33608453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravaginal brachytherapy alone for intermediate-risk endometrial cancer.
    Alektiar KM; Venkatraman E; Chi DS; Barakat RR
    Int J Radiat Oncol Biol Phys; 2005 May; 62(1):111-7. PubMed ID: 15850910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patterns of recurrence in stage I endometrioid endometrial adenocarcinoma with lymphovascular space invasion.
    Simpkins F; Papadia A; Kunos C; Michener C; Frasure H; AbuShahin F; Mariani A; Bakkum-Gamez JN; Landrum L; Moore K; Thomas SG; Windhorn A; Rose PG
    Int J Gynecol Cancer; 2013 Jan; 23(1):98-104. PubMed ID: 23221731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymph-vascular space involvement and outer one-third myometrial invasion are strong predictors of distant haematogeneous failures in patients with stage I-II endometrioid-type endometrial cancer.
    Gadducci A; Cavazzana A; Cosio S; DI Cristofano C; Tana R; Fanucchi A; Teti G; Cristofani R; Genazzani AR
    Anticancer Res; 2009 May; 29(5):1715-20. PubMed ID: 19443392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of adjuvant therapy in stage IIIC2 endometrial cancer.
    Bogani G; Cappuccio S; Casarin J; Narasimhulu DMM; Cilby WA; Glaser GE; Weaver AL; McGree ME; Keeney GL; Weroha J; Petersen IA; Mariani A
    Int J Gynecol Cancer; 2020 Aug; 30(8):1169-1176. PubMed ID: 32646864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer--A pooled analysis of PORTEC 1 and 2 trials.
    Bosse T; Peters EE; Creutzberg CL; Jürgenliemk-Schulz IM; Jobsen JJ; Mens JW; Lutgens LC; van der Steen-Banasik EM; Smit VT; Nout RA
    Eur J Cancer; 2015 Sep; 51(13):1742-50. PubMed ID: 26049688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sentinel lymph node (SLN) isolated tumor cells (ITCs) in otherwise stage I/II endometrioid endometrial cancer: To treat or not to treat?
    Backes FJ; Felix AS; Plante M; Grégoire J; Sullivan SA; Rossi EC; Tanner EJ; Stewart KI; Soliman PT; Holloway RW; Abu-Rustum NR; Leitao MM
    Gynecol Oncol; 2021 May; 161(2):347-352. PubMed ID: 33678480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcomes in international federation of gynecology and obstetrics stage IA endometrial cancer with myometrial invasion treated with or without postoperative vaginal brachytherapy.
    Diavolitsis V; Rademaker A; Lurain J; Hoekstra A; Strauss J; Small W
    Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):415-9. PubMed ID: 22365625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors for tumor recurrence in endometrioid endometrial cancer stages IA and IB.
    Han KH; Kim HS; Lee M; Chung HH; Song YS
    Medicine (Baltimore); 2017 May; 96(21):e6976. PubMed ID: 28538399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant treatment improves overall survival in women with high-intermediate risk early-stage endometrial cancer with lymphovascular space invasion.
    Son J; Chambers LM; Carr C; Michener CM; Yao M; Beavis A; Yen TT; Stone RL; Wethington SL; Fader AN; Burkett WC; Richardson DL; Staley AS; Ahn S; Gehrig PA; Torres D; Dowdy SC; Sullivan MW; Modesitt SC; Watson C; Veade A; Ehrisman J; Havrilesky L; Secord AA; Loreen A; Griffin K; Jackson A; Viswanathan A; Ricci S
    Int J Gynecol Cancer; 2020 Nov; 30(11):1738-1747. PubMed ID: 32771986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumour-free distance from serosa is a better prognostic indicator than depth of invasion and percentage myometrial invasion in endometrioid endometrial cancer.
    Chattopadhyay S; Galaal KA; Patel A; Fisher A; Nayar A; Cross P; Naik R
    BJOG; 2012 Sep; 119(10):1162-70. PubMed ID: 22804815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of tumor-free distance and depth of myometrial invasion as prognostic factors for lymph node metastases in endometrial cancer.
    Kondalsamy-Chennakesavan S; van Vugt S; Sanday K; Nicklin J; Land R; Perrin L; Crandon A; Obermair A
    Int J Gynecol Cancer; 2010 Oct; 20(7):1217-21. PubMed ID: 21495232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma.
    Cirisano FD; Robboy SJ; Dodge RK; Bentley RC; Krigman HR; Synan IS; Soper JT; Clarke-Pearson DL
    Gynecol Oncol; 2000 Apr; 77(1):55-65. PubMed ID: 10739691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.